FDA Device Intelligence
Home › Nuclein, LLC › DASH® SARS-CoV-2 & Flu A/B Test Kit

DASH® SARS-CoV-2 & Flu A/B Test Kit

Nuclein, LLC · Model SG-0006 · UDI-DI 00850063063036

QOF Prescription
1
510(k) clearances
49
Adverse events
9
Recalls
31
Facilities

Description

The DASH SARS-CoV-2 & Flu A/B Test is a rapid reverse transcription polymerase chain reaction (RT-PCR) assay performed on the DASH Rapid PCR Instrument and is intended for the simultaneous in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A and influenza B virus ribonucleic acid (RNA) in anterior nasal swab specimens from patients with signs and symptoms of respiratory tract infection. The test is intended to aid in the differential diagnosis of SARS-CoV-2, influenza A, and influenza B in humans in conjunction with other clinical, epidemiologic and laboratory findings. Positive results of a specific target are indicative of the presence of that viral RNA and may not be the definite cause of disease. Positive results do not rule out co-infection with other pathogens. Negative results do not preclude SARS-CoV-2, influenza A or influenza B infection and should not be used as the sole basis for patient management decisions.

Recalls

DateFirmReason
2026-06-24BioFire Diagnostics, LLCDue to increase in false negative results
2026-04-01BioFire Diagnostics, LLCRespiratory/sore throat panel test may result in false negative results and control failures.
2025-10-22BioFire Diagnostics, LLCDue to unintended movement of pouch chemistry, nucleic acid test may result in elevated risk of false negative results and risk of control failures.
2025-06-25Nuclein LLCDue to manufacturing error, assay test may result in missed diagnosis or delay of treatment. (Potential false negative result)
2025-03-12Qiagen Sciences LLCIdentified faulty cartridges. If such a faulty cartridge is used for sample testing, false test results could occur.
2024-11-08Hologic, Inc.SARS-CoV-2/Flu A/B/RSV Assay Kit may erroneously produce SARS-CoV-2 false positive results.
2023-11-27BioFire Diagnostics, LLCA manufacturing event may contribute to elevated rates of false negative results while using gastrointestinal panel and respiratory panel, which could lead to inappropriate antibio
2023-05-08BioFire Diagnostics, LLCDue to manufacturing issue, panels may result in false negative results.
2023-02-01BioFire Diagnostics, LLCDue to temperature excursions with products (products being stored outside of the required temperature specifications) that may cause a reduction in performance. The temperature e

Query this across every FDA database — by API.

Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.

Get your free API keyRead the docs
Data compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.